by 
Market Overview:
Autologous stem cell and non-stem cell based therapies involve the use of adult stem cells harvested from the patient’s own body to treat diseases, injuries or conditions. These therapies help repair or replace damaged tissues and cells and help restore normal functioning. They are used in treatment of various chronic diseases like neurological disorders, cardiovascular diseases, arthritis and bone & joint related disorders. Autologous therapies have minimal risk of rejection, infection or complication and do not involve complex processing or manipulation of stem cells. This has accelerated their adoption worldwide. The global autologous stem cell and non-stem cell based therapies market is driven by rapidly aging population, increasing prevalence of chronic diseases, advancements in stem cell biology and technological innovations. However, high costs and lack of effective collection and storage methods pose challenges.
The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the Autologous Stem Cell and Non-Stem Cell Based Therapies are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.
Growing prevalence of chronic diseases worldwide especially cardiovascular, neurological disorders and musculoskeletal conditions is driving increasing demand for autologous stem cell therapies. According to WHO, chronic diseases accounted for over 70% deaths globally in 2020.
Major players are expanding their operations globally especially in emerging markets of Asia Pacific and Latin America to tap the large untapped market potential. For instance, Vericel Corporation inaugurated new production facilities in India and China in 2023 to cater to the Asian markets.
Market Key Trends
One of the key trends gaining traction in the autologous stem cell and non-stem cell based therapies market is use of microfluidics cell separation technology. This technology allows for precise and rapid isolation of adult stem cells from small tissue or blood samples with high purity and viability. Companies are developing novel microfluidic devices for automated, point-of-care stem cell collection and processing to expand access and reduce costs. This is expected to positively influence the market over the forecast period.
Porter’s Analysis
Threat of new entrants: Low barriers to entry due to industry attractiveness and easy availability of advanced technologies.
Bargaining power of buyers: Limited buyer power due to availability of limited product alternatives and options.
Bargaining power of suppliers: High supplier power due to limited number of raw material suppliers and established supply chains.
Threat of new substitutes: Low threat due to lack of close substitutes and established product technologies.
Competitive rivalry: Intense competition among existing players to gain higher market share through product innovations and strategic collaborations.
Geographical Regions
North America dominates the global market owing to availability of advanced healthcare infrastructure and growing prevalence of chronic diseases. The United States accounts for the largest share in the region due to established healthcare facilities and presence of leading market players.
Asia Pacific exhibits the fastest growth in the forecast period driven by expanding healthcare infrastructure, rising medical tourism, and growing geriatric population base in countries like China, India and Japan.
